Abstract:Background Currently, no ideal biomarker can accurately stratify the risk of patients with severe community-acquired pneumonia (SCAP). This study aimed to evaluate the role of serum Krebs von den Lungen-6 (sKL-6) in predicting in-hospital mortality in adults with SCAP. Methods In this retrospective cohort study, 249 severe pneumonia adult patients were recruited between 6 May 2021 to 30 April 2023 in Xiangya Hospital of Central South University. The sKL-6 level within 48 h of admission was measured, and the primary outcome assessed was in-hospital mortality. Multivariable logistic regression analysis was performed to calculate adjusted odds ratios (aOR) with 95% confidence intervals (CI). Survival curves were plotted and subgroup analyses were conducted, stratified by relevant covariates. Results A total of 249 patients were included in the study,with 124 patients having normal sKL-6 levels, and 125 patients having abnormal sKL-6 levels The overall in-hospital mortality rate was 28.9% (72 out of 249 patients). Univariate and multivariate logistic regression analysis revealed that the patients with abnormal sKL-6 levels had a higher risk of in-hospital mortality compared to those with normal sKL-6 levels, both in the total SCAP patient population (aOR: 5.38, 95%CI: 2.41-12.01, P < 0.001) and the non-COVID-19 SCAP patients subgroup (aOR: 8.12, 95%CI: 3.16-20.84, P < 0.001). Subgroup and interaction analyses confirmed the stability of the relationship between sKL-6 levels and in-hospital mortality( P for interaction >0.05). Kaplan-Meier survival curves showed that patients with abnormal sKL-6 levels had a higher in-hospital mortality rate than those with normal sKL-6 levels ( P <0.05). However, the results of restricted cubic spline plots(RCS) analysis demonstrated a nonlinear association between sKL-6 level (as a continuous variable) and in-hospital mortality in patients with SCAP. Similar results were observed in non-COVID-19 SCAP patients. Furthermore, the receiver operating characteristic curve (ROC) analysis revealed that sKL-6 had superior predictive performance compared to existing biomarkers (e.g., APACHE-II, SOFA, BUN/Cr, PCT, and D-dimer) for in-hospital mortality in non-COVID-19 SCAP patients . Conclusion sKL-6 is a practical and useful biomarker for predicting in-hospital mortality in patients with SCAP.

Associations of the Serum KL-6 with Severity and Prognosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Serum Levels of IGFBP7 Are Elevated During Acute Exacerbation in COPD Patients.

Serum Krebs von den Lungen-6 as a potential biomarker for distinguishing combined pulmonary fibrosis and emphysema from chronic obstructive pulmonary disease: A retrospective study

Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis

Determination of Biomarkers in Exhaled Breath Condensation of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Clinical Implications

KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis

Research progress of KL-6 in respiratory system diseases

Serum Krebs Von Den Lungen-6 Level As A Diagnostic Biomarker For Interstitial Lung Disease In Chinese Patients

AB1226 The diagnostic value of serum kl-6 in connective tissue disease associated interstitial lung disease

Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019

[The Clinical Significance of the Levels of Serum KL-6 Mucin and Interleukin-13 in Pulmonary Alveolar Proteinosis].

Serum Krebs von den Lungen-6 Is Associated with in-Hospital Mortality of Patients With Severe Community-Acquired Pneumonia: A Retrospective Cohort Study

Role of BAL and Serum Krebs von den Lungen-6 (KL-6) in Patients with Pulmonary Fibrosis

Diagnostic Value of Serum KL-6 in Interstitial Lung Diseases

An in-depth investigation of serum Krebs von den Lungen-6 and other biomarkers in COVID-19 severity and mortality

Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients

Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases

Fibrosis and Damage Markers in Occupational Interstitial Lung Diseases

Serum Inflammatory Factor and Cytokines in AECOPD

Expression and clinical significance of biomarkers in serum and bronchoalveolar lavage fluid from patients with connective tissue disease-associated interstitial lung disease

Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features